Abbott will expand the current CE-IVD product labeling for its Vysis ALK Break Apart FISH Probe Kit to allow the test to be marketed in the European Union as a companion diagnostic. The test uses Abbott's proprietary fluorescence in situ ...
Tags: Abbott, anaplastic lymphoma kinase, ALK, FISH technology
BioView and Abbott have entered into a partnership agreement for the development of automated scanning solution to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in patients with advanced non-small cell lung cancer ...
Tags: BioView, Abbott, automated scanning solution, NSCLC
Pfizer Canada has announced the availability of Xalkori (crizotinib) for patients with anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC) in Canada. A validated ALK assay should be used to ...
Tags: ALK, ALK-positive lung cancer, Pfizer Canada
The SFJ Pharmaceuticals Group (SFJ) has partnered with Pfizer to co-develop Dacomitinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal ...
Tags: Cancer Drug, cell lung cancer, therapy
Eli Lilly and Company Alimta(pemetrexed for injection)has received FDA approval for new use in the continuation maintenance setting for advanced or metastatic nonsquamous non-small cell lung cancer(NS NSCLC). The approval was based on ...
The US Patent and Trademark Office (USPTO) has issued a notice of allowance for CytRx Corporation's patent application covering a pharmaceutical composition of tamibarotene in capsule form. Tamibarotene is an orally available, ...
Tags: notice of allowance, patent application, tamibarotene, USPTO